Alcon has acquired a majority interest in Aurion Biotech, according to a press release. Aurion will operate as a separate ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

Slit lamp examination revealed bilateral corneal stromal edema and corneal guttata consistent with Fuchs' endothelial dystrophy. On postoperative day one, corneal graft displacement (eccentric ...

Immediately postoperatively, corneal graft displacement and peripheral corneal edema which remained stable during the first postoperative month were evident on slit lamp examination. Three months ...

Dublin, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The "Corneal Edema - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. A comprehensive report has been released ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...